TY - JOUR T1 -支气管扩张患者中性粒细胞功能障碍:an emerging role for immunometabolism(免疫代谢的新角色)N2 -支气管扩张是一种有多种潜在原因的异质性疾病。其病理生理学尚不清楚，但嗜中性粒细胞炎症和功能失调的病原体杀死被认为是关键。然而，目前还没有针对中性粒细胞炎症的经许可的支气管扩张疗法。在这篇综述中，我们讨论了我们目前对中性粒细胞功能障碍和支气管扩张治疗靶点的理解。免疫代谢重编程是炎症通过改变细胞内代谢途径改变炎症细胞行为的过程，在多种炎症和自身免疫性疾病中越来越被认识到。在这里，我们显示的证据表明，在支气管扩张中观察到的许多中性粒细胞功能障碍与免疫代谢重编程一致。以前开发针对中性粒细胞的疗法的尝试侧重于减少中性粒细胞数量，从而导致感染增加。我们需要新的方法，我们提出靶向代谢理论上可以逆转中性粒细胞功能障碍和炎症失调。 As an exemplar, AMPK activation has already been shown to reverse phagocytic dysfunction and neutrophil extracellular trap formation in models of pulmonary disease. AMPK modulates multiple metabolic pathways including glycolysis which is critical for energy generation in neutrophils. AMPK activators can reverse metabolic reprogramming and are already in clinical use and/or development. We propose the need for a new immunomodulatory, rather than anti-inflammatory, approach to enhance bacterial clearance and reduce bronchiectasis disease severity.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Giam has nothing to disclose.Conflict of interest: Dr. Shoemark has nothing to disclose.Conflict of interest: Dr. Chalmers reports grants and personal fees from Astrazeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work;. ER -